SMYD2 and hepatocellular carcinoma: In a large series comprised of 163 primary HCC cases, 74.8% stained positive for SMYD2 using immunohistochemistry, and tumors displaying SMYD2 immunopositivity were significantly associated with vascular invasion, larger tumor size, higher TNM stage and moderate to poorly differentiated phenotypes [32].